Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 7/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | MAP3K5 | Q99683 | 8/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31543411 | 0.88 | MAPK1 (0.54) | MAPK1EGFRMAP3K5PLK1 | |
| SCHEMBL31543078 | 0.87 | MAPK1 (0.53) | MAPK1EGFRMAP3K5PLK1 | |
| SCHEMBL26685698 | 0.87 | MAPK1 (0.53) | MAPK1EGFRMAP3K5PLK1 | |
| SCHEMBL31543297 | 0.85 | MAPK1 (0.50) | MAPK1EGFRPLK1JAK1TYK2 | |
| SCHEMBL26685467 | 0.83 | MAPK1 (0.54) | MAPK1EGFRMAP3K5PLK1JAK1 | |
| SCHEMBL31543230 | 0.83 | MAPK1 (0.54) | MAPK1EGFRMAP3K5PLK1JAK1 | |
| SCHEMBL31543182 | 0.82 | MAPK1 (0.54) | MAPK1EGFRMAP3K5PLK1 | |
| SCHEMBL31543309 | 0.81 | MAPK1 (0.53) | MAPK1EGFRMAP3K5 | |
| SCHEMBL31543073 | 0.81 | MAPK1 (0.51) | MAPK1EGFRMAP3K5PLK1JAK1 | |
| SCHEMBL30632858 | 0.79 | MAPK1 (0.52) | MAPK1EGFRMAP3K5PLK1JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304577-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2025-10-02 | — | — | US | disclosed |
| CN-119654322-A | TYK2 inhibitors | 渤健马萨诸塞州股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304577-A1 | TYK2 INHIBITORS | TYK2, JAK2, JAK1 | MAPK1 228/4885EGFR 380/4885MAP3K5 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.